ATE292976T1 - Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung - Google Patents

Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung

Info

Publication number
ATE292976T1
ATE292976T1 AT99922905T AT99922905T ATE292976T1 AT E292976 T1 ATE292976 T1 AT E292976T1 AT 99922905 T AT99922905 T AT 99922905T AT 99922905 T AT99922905 T AT 99922905T AT E292976 T1 ATE292976 T1 AT E292976T1
Authority
AT
Austria
Prior art keywords
cell survival
blood cell
white blood
mobilization
producing
Prior art date
Application number
AT99922905T
Other languages
English (en)
Inventor
Kathleen Rodgers
Gere Dizerega
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE292976T1 publication Critical patent/ATE292976T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0819Tripeptides with the first amino acid being acidic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1021Tetrapeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/14Angiotensins: Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99922905T 1998-05-11 1999-05-10 Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung ATE292976T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8490898P 1998-05-11 1998-05-11
US9263398P 1998-07-13 1998-07-13
PCT/US1999/010205 WO1999058140A1 (en) 1998-05-11 1999-05-10 Methods to increase white blood cell survival after chemotherapy

Publications (1)

Publication Number Publication Date
ATE292976T1 true ATE292976T1 (de) 2005-04-15

Family

ID=26771571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922905T ATE292976T1 (de) 1998-05-11 1999-05-10 Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung

Country Status (8)

Country Link
US (2) US6475988B1 (de)
EP (1) EP1073453B1 (de)
JP (1) JP2003521441A (de)
AT (1) ATE292976T1 (de)
AU (1) AU759285B2 (de)
CA (1) CA2322963C (de)
DE (1) DE69924715T2 (de)
WO (1) WO1999058140A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
JP2002509077A (ja) * 1998-02-09 2002-03-26 ユニヴァースティ オブ サザーン カリフォルニア 赤血球形成促進方法
US7173011B2 (en) * 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6762167B1 (en) * 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) * 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) * 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) * 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
ES2975413T3 (es) * 2001-12-17 2024-07-05 Univ Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas
EP1485116A4 (de) * 2002-02-27 2006-06-07 Univ Wake Forest Angiotensin-(1-7)- und angiotensin-(1-7)-agonisten zur hemmung des krebszellenwachstums
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
EP2455388A1 (de) 2010-11-23 2012-05-23 LanthioPep B.V. Neuartige Rezeptoragonisten von Angiotensin des Typs 2 (AT2) und Verwendungen dafür
EP2536422B8 (de) 2011-02-02 2023-06-21 University of Southern California Verfahren zur behandlung von diabetischen fussgeschwüren
EP2849773A1 (de) 2012-05-14 2015-03-25 University of Southern California Verfahren zur begrenzung der entwicklung einer hautwunde
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
EP2968441A1 (de) 2013-03-15 2016-01-20 University of Southern California Verfahren zur behandlung von multipler sklerose
AU2014233185B2 (en) 2013-03-15 2018-03-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
AU2014284496A1 (en) 2013-07-03 2016-01-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
EP3171886A4 (de) 2014-07-21 2018-01-24 The Arizona Board of Regents On Behalf of the University of Arizona Ang-(1-7)derivat-oligopeptide und verfahren zur verwendung und herstellung davon
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
US5527882A (en) * 1989-07-07 1996-06-18 The Regents Of The University Of California Polypeptide having an amino acid replaced with N-benzylglycine
CA2044468C (en) * 1990-11-21 2006-08-22 Richard A. Nash Canine granulocyte macrophage colony stimulating factor
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
DE69435301D1 (de) 1993-09-24 2010-08-26 Univ Southern California Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
ES2168312T3 (es) 1993-09-24 2002-06-16 Univ Southern California Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3403794B2 (ja) * 1994-01-27 2003-05-06 仙味エキス株式会社 血圧降下剤及び血圧降下性機能食品
US5739110A (en) * 1994-09-12 1998-04-14 Biomeasure Inc. Protection of hemopoietic cells
US5595973A (en) 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
US5614515A (en) 1994-11-17 1997-03-25 University Of Southern California Lazaroid-based compositions and method for preventing adhesion formation using the same
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
JPH11507038A (ja) 1995-06-07 1999-06-22 ユニヴァースティ オブ サザーン カリフォルニア 5−リポキシゲナーゼ阻害剤を用いる、術後癒着形成を低減又は阻止する方法
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
WO1997034627A2 (en) * 1996-03-19 1997-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. Protection of hemopoietic cells during chemotherapy or radiotherapy
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU6650098A (en) 1997-02-04 1998-08-25 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
EP1047441A1 (de) * 1997-11-26 2000-11-02 University Of Southern California Verfahren zur förderung der proliferation und differenzierung von hämatopoietischen und mesenchymalen zellen
CA2315266C (en) * 1997-12-12 2004-08-10 University Of Southern California Wound healing compositions
JP2002509077A (ja) * 1998-02-09 2002-03-26 ユニヴァースティ オブ サザーン カリフォルニア 赤血球形成促進方法

Also Published As

Publication number Publication date
DE69924715T2 (de) 2006-01-26
US6475988B1 (en) 2002-11-05
EP1073453A1 (de) 2001-02-07
EP1073453B1 (de) 2005-04-13
CA2322963A1 (en) 1999-11-18
AU759285B2 (en) 2003-04-10
AU3979899A (en) 1999-11-29
CA2322963C (en) 2004-04-13
DE69924715D1 (de) 2005-05-19
US6566335B1 (en) 2003-05-20
JP2003521441A (ja) 2003-07-15
WO1999058140A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
DE69924715D1 (de) Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
IL116385A0 (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE319812T1 (de) Knochen-vorläufer-zellen: zusammensetzungen und methoden
ITPD920071A1 (it) Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
AU6331898A (en) Forskohlin for promoting lean body mass
AP9801269A0 (en) Prostaglandin agonists.
HUP0301349A2 (hu) IL-11-tartalmú készítmények
DE60118558D1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
IL153147A0 (en) Phospholipid derivatives of valporic acid and mixtures thereof
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE250422T1 (de) Komponenten mit niedrigem molekulargewicht aus knorpelgewebe von haien, verfahren zur herstellung und therapeutische verwendungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties